An interventional study of 3% kanuka oil in Dermatitis, Atopic and Pruritus, sponsored by Nexgen Dermatologics, Inc.. Recruiting at 1 site in United States. Open to participants aged 12 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by Nexgen Dermatologics, Inc. · Not applicable, Interventional, and Treatment
Atopic dermatitis is a common disease affecting millions worldwide. A common associated symptom in this population is pruritus. We seek to investigate the use of an natural, over-the-counter cosmeceutical to help this population
There are many treatment options available for atopic dermatitis yet many patients still suffer from the underlying symptomatology. It is important to explore other treatment alternatives to help this population.
1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.
This study's planned enrollment of 60 is below the median of 83 across 1,125 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Nexgen Dermatologics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
3% kanuka oil cream will be applied topically to the affected area twice a day for 28 days
Other: 3% kanuka oil
1% Hydrocortisone Cream will be applied topically to the affected area twice a day for 28 days
Other: 3% kanuka oil
To assess the efficacy in patients with mild atopic dermatitis, 3% kanuka oil will be applied twice a day for 28 days. 3% kanuka oil is a naturally occurring extract from the kanuka tree and is considered an over-the-counter agent.
ISGA
Investigator scale to determine imporvement in condition
Time frame: 28 days
WI-NRS
Scale generated by patient's responses to survey questions to assess improvement in itch
Time frame: 28 days
Plan to share: No — The individual participant data will be confidential and not shared unless authorized by the participant
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nexgen Dermatologics, Inc.